Collaborative Medicinal Development LLC (“CMD”) is an early-stage pharmaceutical research-and-development company that’s dedicated to developing a growing portfolio of proprietary and in-licensed medicines and treatments for neuro-degenerative and other debilitating conditions and diseases. Organizationally, each initiative is set up in a separate CMD subsidiary to allow for maximum flexibility in terms of partnering, staffing, and funding….with two of those subsidiaries, Oncochel Therapeutics and Procypra Therapeutics, currently engaged in Phase 1 trials targeting treatment-resistant cancer and ALS/Parkinson’s Disease, respectively.